Pioneering Glioblastoma Treatment with GlioHook
Batea Oncology develops innovative therapies for glioblastoma , with the aim of improving treatment outcome and patient survival rates.
The company
Pushing forward new therapeutic strategies for glioblastoma
Batea Oncology is a biotech company focused on the development of new therapeutic solutions to tackle aggressive cancers with low survival.
Glioblastoma is the deadliest and most common malignant primary brain tumor, treated with a combination of surgery plus chemoradiotherapy. Still, local recurrences occur in 90% of cases and 5-year survival rate is <5%.
Resection surgery is challenging and often incomplete, and residual cancer cells, highly resistant to radiotherapy, end up infiltrating the brain tissue.
The standard of care for glioblastoma has remained unchanged for the last 20 years.
At Batea Oncology we aim at changing this scenario through innovation. We have developed GlioHook, a medical device for the treatment of glioblastoma patients.
Our technology
Capturing cancer cells to transform treatment. A new approach in the fight against Glioblastoma
Our first asset is GlioHook, a class III medical device for the treatment of glioblastoma patients. It concentrates tumor cells remaining after surgery in an artificial and controlled location, changing the disease from an infiltrative to a focalized one. At the same time, GlioHook renders cancer cells more sensitive to radiotherapy.
Combining disease focalization and radio-sensitization offers a new treatment paradigm
GlioHook is designed to be implanted after GB resection surgery, in contact with the surgical margins. In preclinical animal models GlioHook is safe, and increases survival compared to radiotherapy alone.
All this, without changing the standard clinical practice, and taking advantage of a therapeutic window currently unused, until radiotherapy is administered.
Our aim is to translate this technology into patients in a Phase I clinical trial, starting in 2025.
Innovation approach
Why GlioHook is a game-changer in Glioblastoma Treatment?
In close contact
Targeting tumor relapse at its source. GlioHook is directly exposed to residual tumor cells at surgical margins, the main responsible of relapse
No time to lose
GlioHook covers a therapeutic gap (1-2 months) until the onset of radiotherapy , taking advantage of a precious time for the patients
Focus & Boost
GlioHook induces disease focalization, reduces infiltration and improves the effect of radiotherapy
Unlocking synergies
GlioHook can be combined with the current standard of care and with new therapies under developments such as immunotherapies.
Streamlined production
GlioHook is easily scalable for manufacturing
Seamless integration
GlioH ook is implanted at the moment of surgical resection with no extra require ments, adapting to the current standard of care
Our team
Complementary and experienced leadership team
Batea Oncology core team gathers a multidisciplinary combination of experts in cancer research , medical oncologists, neurosurgeons, and experienced biotech entrepreneurs.
Sonia Martínez Arca, PhD
CEO
+15y experience in executive management in public and private entities in life sciences.
Entrepreneur with strategic and hands on experience as founder and CEO of three companies.
Jorge Barbazán, PhD
CSO
Expert in cancer metastasis, biomaterials and tumor microenvironment.
Alba Ferreirós, PhD
Senior Scientist
Specialist in GBM animal tumor models and pre-clinical development.
Eladio Crego, MBA
Financial Advisor
Rafael López, MD, PhD
Clinical Advisor
Miguel Abal, PhD
Scientific Advisor
+ 30y experience in oncology and translational research.
Supported by:
Member of:
